Spinal malignant triton tumor in a patient with neurofibromatosis type 1

Year 2019, Volume: 5 Issue: 4, 719 - 721, 04.07.2019

Sevgi Kulaklı , Fazıl Kulaklı , İlker Fatih Sarı , Samet Tatlı İlker İlhanlı , Canan Çelik

https://doi.org/10.18621/eurj.464297

Abstract

No abstract available.

Keywords

malignant triton tumor, Neurofibromatosis, spinal nerve

References

• [1] Jouhilahti EM, Peltonen S, Heape AM, Peltonen J. The pathoetiology of neurofibromatosis 1. Am J Pathol 2011;178:1932-9.
• [2] Engel EE, Brassesco MS, Valera ET, Barbosa MHN,Yamashita MEAS, Scrideli CA, et al. Clinico-genetic aspects of a pediatric non-neurofibromatosis type 1 malignant triton tumor with loss of chromosome X. Pediatr Blood Cancer 2012;59:1320-3.
• [3] Kamran SC, Howard SA, Shinagare AB, Krajewski KM. Malignant peripheral nerve sheath tumors: prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location. EJSO 2013;39:46-52.
• [4] McConnell YJ, Giacomantonio CA. Malignant triton tumors--complete surgical resection and adjuvant radiotherapy associated with improved survival. J Surg Oncol 2012;106:51-6.
• [5] Lee MJ, Stephenson DA. Recent developments in neurofibromatosis type 1. Curr Opin Neurol 2007;20:135-41.
• [6] Stucky CC, Johnson KN, Gray RJ, Pockaj BA, Ocal IT, Rose PS, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol 2012;19:878-85.
• [7] Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol 2008;97:340-9.
• [8] Ferner RE, Gutmann DG. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis 1. Cancer Res 2002;62:1573-7.
• [9] Moretti VM, Crawford EA, Staddon AP, Lackman RD, Ogilvie CM.. Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy. Am J Clin Oncol 2011;34:417-21.